Investment Analysts’ Weekly Ratings Updates for Beam Therapeutics (BEAM)

A number of firms have modified their ratings and price targets on shares of Beam Therapeutics (NASDAQ: BEAM) recently:

• 2/28/2026 – Beam Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 2/25/2026 – Beam Therapeutics had its price target raised by Royal Bank Of Canada from $22.00 to $26.00. They now have a “sector perform” rating on the stock.
• 2/25/2026 – Beam Therapeutics had its price target raised by Wedbush from $57.00 to $65.00. They now have an “outperform” rating on the stock.
• 2/20/2026 – Beam Therapeutics is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $74.00 price target on the stock.
• 2/20/2026 – Beam Therapeutics is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $74.00 price target on the stock.
• 2/8/2026 – Beam Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 1/31/2026 – Beam Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 1/21/2026 – Beam Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/21/2026 – Beam Therapeutics was given a new $41.00 price target by Tudor Pickering.
• 1/20/2026 – Beam Therapeutics had its price target raised by Sanford C. Bernstein from $37.00 to $41.00. They now have an “outperform” rating on the stock.
• 1/11/2026 – Beam Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Buying and Selling

In other news, insider Christine Bellon sold 18,629 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $34.61, for a total transaction of $644,749.69. Following the completion of the transaction, the insider directly owned 97,038 shares in the company, valued at approximately $3,358,485.18. This represents a 16.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 3.50% of the stock is owned by corporate insiders.

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.